WUXI BIOLOGICS CAYMAN INC

Overview

WuXi Biologics (Cayman) Inc. is a biologics contract research, development and manufacturing organization (CRDMO). Its end-to-end platform supports clients from biologic discovery and development through manufacturing, including work on monoclonal antibodies, bispecific antibodies, antibody-drug conjugates and recombinant proteins. The company describes its purpose as enabling global clients to develop and manufacture biologics through this platform.[1][2]

The company serves the biopharmaceutical sector through an international operating network, with reported operations in the United States and facilities in Ireland and Germany. At the end of 2025, it reported 13,252 employees and 15 GMP-certified manufacturing facilities; revenue for 2025 was RMB21.79 billion.[3]+3 [1]+5

Products & services

WuXi Biologics provides contract research, development and manufacturing services for biologic medicines. Its work spans antibody discovery, cell-line and process development, IND-enabling development, technology transfer, and clinical- and commercial-scale GMP manufacturing. The modalities it handles include monoclonal antibodies, bi- and multi-specific antibodies, antibody–drug conjugates (ADCs), fusion proteins, other proteins and vaccines.[7]+2

Its named technologies include WuXiBody, a platform for designing bispecific antibodies; WuXia TrueSite, a targeted-integration cell-line platform; WuXiDARx, a platform for producing ADCs with controlled drug-to-antibody ratios; and WuXiHigh, a high-concentration formulation platform supporting concentrations up to 240 mg/mL. Drug-product capabilities cover liquid and lyophilized vials, prefilled and safety syringes, and autoinjectors.[10]+5

The company reported that bi- and multi-specific antibody work accounted for nearly 20% of group revenue in 2025. Its reported project counts by modality are not revenue shares.[16][9] [7]+9

Geographic presence

WuXi Biologics serves customers across North America, Europe, China and other markets. In 2025, North America accounted for 58.1% of revenue, the European Union for 23.1%, China for 12.3% and the rest of the world for 6.5%. The rest-of-world category primarily included Singapore, Japan, South Korea, Australia and Brazil.[17]

The company identifies U.S. sites in Robbinsville and Cranbury, New Jersey, for drug-product manufacturing and process development or drug-substance manufacturing, respectively. It also lists a Worcester, Massachusetts, drug-substance facility with a 2028 timeframe. Its facility disclosures refer to a site in Leverkusen, Germany, and a separate WuXi Vaccines site in Ireland; both are excluded from the reported count of 15 certified GMP manufacturing facilities.[3]+2 [17]+3

Business segments

WuXi Biologics presents a revenue breakdown by project stage rather than naming separate businesses in the available breakdown. Its categories are Pre-IND work, Post-IND early-phase work (Phase I/II), Late+CMO (late-stage projects and contract manufacturing), and Others. In 2025, these accounted for approximately 42.7%, 12.1%, 43.4% and 1.7% of revenue, respectively. These are project-stage categories, not a verified list of formal reportable operating segments.[19]

A separate geographic breakdown attributes 2025 revenue to North America (58.1%), the European Union (23.1%), China (12.3%) and the rest of the world (6.5%). These figures describe customer location, not business segments.[17][20] [19]+2

Company history

WuXi Biologics traces its biomanufacturing technology back to a 2010 platform based on random integration for antibody production. In 2017, it began large-scale manufacturing at batch sizes of at least 6,000 liters.[21][22] [21][22]

Sources

• WUXI BIOLOGICS CAYMAN INC — Presentation (2025 Y)
  22 citations

  [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20][21][22]